EMEA-001487-PIP01-13 - paediatric investigation plan | European Medicines Agency (EMA)Skip to main content
EMEA-001487-PIP01-13 - paediatric investigation plan
Gevokizumab
PIPHuman
Key facts
Active Substance
Gevokizumab
Therapeutic area
Ophthalmology
Decision number
P/0148/2014
PIP number
EMEA-001487-PIP01-13
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of chronic non-infectious uveitis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Les Laboratoires SERVIER
France E-mail: cafaro@xoma.com Tel. +1 5105415034 Fax +1 5102952724
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date
Decision
P/0148/2014: EMA decision of 13 June 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for gevokizumab (EMEA-001487-PIP01-13)